Establishment of a Prognostic Model and Tumor Clustering for Pediatric Acute Myeloid Leukemia Patients: Leveraging the Fanconi Anemia Signaling Pathway to Enhance Clinical Management

Establishment of a Prognostic Model and Tumor Clustering for Pediatric Acute Myeloid Leukemia Patients: Leveraging the Fanconi Anemia Signaling Pathway to Enhance Clinical Management

In November 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Open Medicine(Wars). The title of the study is "Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients". This study heralds the establishment of a novel prognostic model and tumor clustering approach tailored specifically for pediatric AML, anchored in the FA signaling pathway.
Long-Term Outcome of Rabbit Anti-Thymocyte Globulin and Cyclosporine Therapy for Pediatric Severe Aplastic Anemia

Long-Term Outcome of Rabbit Anti-Thymocyte Globulin and Cyclosporine Therapy for Pediatric Severe Aplastic Anemia

In May 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Blood Science. The title of the study is "An investigation of long-term outcome of rabbit anti-thymocyte globulin and cyclosporine therapy for pediatric severe aplastic anemia". This study holds significant implications for the clinical management of pediatric severe aplastic anemia.
Acinetobacter spp. Bloodstream Infection in Hematological Patients: A 10-Year Single-Center Study 

Acinetobacter spp. Bloodstream Infection in Hematological Patients: A 10-Year Single-Center Study 

In November 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——BMC Infectious Diseases. The title of the study is "Acinetobacter spp. Bloodstream Infection in Hematological Patients: A 10-Year Single-Center Study". This comprehensive study sheds light on the significant burden of Acinetobacter spp. BSI in hematological patients, emphasizing the complexity of treating these infections in a population at high risk of adverse outcomes.
Unraveling the Complexity of Acute Myeloid Leukemia: Insights from Single-Cell Analysis

Unraveling the Complexity of Acute Myeloid Leukemia: Insights from Single-Cell Analysis

In November 2023, a  study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——BMC Bioinformatics. The title of the study is "Detection of continuous hierarchical heterogeneity by single-cell surface antigen analysis in the prognosis evaluation of acute myeloid leukaemia". This study embarks on a pioneering endeavor to decode the continuous hierarchical heterogeneity embedded within AML using single-cell surface antigen analysis.
ABC7|Dr.Javier Cortes:Treatment directions and prospects for HER2+ advanced breast cancer treatment

ABC7|Dr.Javier Cortes:Treatment directions and prospects for HER2+ advanced breast cancer treatment

HER2+ (HER2-positive) breast cancer is a type of breast cancer subtype with strong aggressiveness and poor prognosis. With the approval of more new targeted drugs for clinical application, the prognosis of HER2+ breast cancer patients continues to improve. In the absence of previous anti-HER2 targeted therapy, patients with HER2+ have a higher risk of recurrence. After anti-HER2 therapy, the risk of recurrence is significantly reduced. In recent years, the emergence of antibody-coupled (ADC) drugs has brought the treatment of HER2+ breast cancer patients into a new era, but there are still some unsolved problems. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7), Oncology Frontier invited Dr.Javier Cortes of the Vall d'Hebron Institute of Cancer in Barcelona, Spain, to summarize and look forward to the changes in the field of HER2+ advanced breast cancer.
ABC7 | Dr.Ginny Mason:Working together to help breast cancer patients recover

ABC7 | Dr.Ginny Mason:Working together to help breast cancer patients recover

The decisions faced by cancer patients are often many and complex. At present, the doctor-patient co-decision model is widely used in cancer patients. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7) "Patient advocacy session: Complexities of shared decision making "featured experts discussing complexities of shared decision making among patients.Oncology Frontier invited Dr.Ginny Mason, the host of the show, to introduce the common psychological problems of breast cancer patients and how to deal with them.
ABC7 | Dr.Eric P. Winer:Do a good job of managing advanced breast cancer patients

ABC7 | Dr.Eric P. Winer:Do a good job of managing advanced breast cancer patients

Since the 6th International Consensus Conference on Advanced Breast Cancer (ABC6), the field of advanced breast cancer treatment has changed a lot with the emergence of new therapeutic agents. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7), Oncology Frontier invited Dana-Farber Cancer Institute Dr.Eric P.Winer to share with us the changing treatment of breast cancer.
Dr.Hu Xichun &Hope S. Rugo: Future treatment strategies for advanced triple-negative breast cancer and HR+/ HER2-breast cancer from the perspective of ADC drug treatment progress

Dr.Hu Xichun &Hope S. Rugo: Future treatment strategies for advanced triple-negative breast cancer and HR+/ HER2-breast cancer from the perspective of ADC drug treatment progress

The International Consensus Conference on Advanced Breast Cancer (ABC) is the premier international conference in the academic field of advanced breast cancer, whose primary goal is to develop international consensus guidelines for the management of patients with advanced breast cancer. These guidelines are based on the latest evidence and can be used to guide treatment decisions in many different healthcare Settings around the world. The ABC also aims to identify research priorities based on the most important areas of unmet need, analyze and discuss existing data to provide the most accurate management recommendations, influence policymakers and funding agencies, and ultimately improve standards of care, survival, and quality of life. On the ABC7,Oncology Frontier invited Professor Hu Xichun, Affiliated Cancer Hospital of Fudan University, and Professor Hope S.Rugo, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, to present their views on the diagnosis and treatment concept of advanced triple-negative breast cancer and HR+/ HER2-breast cancer.